Hemispherx Enters into Sale/Leaseback Agreement for NJ Development and Production Facility

by Barry101 | Jan 17, 2018 | Press Release

Transaction helps boost Ampligen production to maximum levelsORLANDO, Fla., Jan. 17, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, today said it has entered into a sale and leaseback agreement for the property it...

Hemispherx Enhances Manufacturing Efficiency of Ampligen

by Barry101 | Jan 11, 2018 | Press Release

New Technology Simplifies, Speeds Production of Immuno-Oncology CandidateORLANDO, Fla., Jan. 11, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB), has successfully tested a new chemical catalyst used in the manufacturing process of Ampligen®, a novel...

Hemispherx Announces Presentation of New-Found Properties of Ampligen at Immuno-Oncology Frontiers Conference, Jan 24

by Barry101 | Jan 9, 2018 | Press Release

Ampligen from Hemispherx Shows Potential to Make Tumors More Responsive to Checkpoint InhibitorsORLANDO, Jan. 09, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, today announced that Pawel Kalinski, MD, PhD, Rustum...

Hemispherx Biopharma CEO Discusses 2017 Highlights on CEOLIVE.TV

by Barry101 | Jan 2, 2018 | Press Release

ORLANDO, Fla., Jan. 02, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB), based in Orlando, FL, focused on pharmaceuticals, today announced that Thomas K. Equels, M.S. J.D., Chief Executive Officer, was interviewed on CEOLIVE.TV on January 2nd, 2018.The...